Therapies in development for community-acquired pneumonia

Expert Opinion on Investigational Drugs
Francesco BlasiPaolo Tarsia

Abstract

The current use of antimicrobials has become more complex due to the extensive emergence of antibiotic resistance. The single most important approach in resistance control is probably the judicious use of chemotherapeutic agents. New agents that may be of use in the treatment of community-acquired pneumonia are currently in development. Antimicrobials can be grouped according to their mechanism of action. These include protein synthesis inhibitors (ketolides, oxazolidinones, streptogramins and glycylcyclines), nucleic acid synthesis inhibitors (fluoroquinolones), peptidoglycan synthesis inhibitors (beta-lactams and glycopeptides) and agents interfering with membrane function (cationic peptides and lipopeptides). Among those agents under development, only the oxazolidinones, the cationic peptides and the lipopeptide antibiotics can be truly regarded as structurally novel inhibitors as the other agents are analogues of existing compounds which have been in clinical use for many years.

References

Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P GeslinJ F Acar
Nov 11, 1991·Antimicrobial Agents and Chemotherapy·W E AlbornD A Preston
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·P CanepariG Satta
Jun 1, 1994·The Journal of Antimicrobial Chemotherapy·K ColemanI Chopra
Aug 1, 1993·Antimicrobial Agents and Chemotherapy·M Arthur, P Courvalin
Dec 1, 1995·Antimicrobial Agents and Chemotherapy·K M KamM M Cheung
Nov 7, 1996·The New England Journal of Medicine·H S Gold, R C Moellering
Mar 1, 1997·Applied and Environmental Microbiology·C JohansenT Abee
Mar 1, 1997·Antimicrobial Agents and Chemotherapy·I ChopraG Poste
Jun 1, 1997·Trends in Microbiology·T I NicasD K Braun
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·A BonnefoyJ F Chantot
Oct 6, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H SongC H Pai
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·D L ShinabargerJ M Buysse
Jun 13, 1998·International Journal of Antimicrobial Agents·M SouliG M Eliopoulos
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R C Moellering
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G V DoernR N Jones
Dec 3, 1998·Antimicrobial Agents and Chemotherapy·S M SwaneyD L Shinabarger
Mar 6, 1999·Current Opinion in Microbiology·I Chopra
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·Y GeM Zasloff
Jun 1, 1999·The Journal of Antimicrobial Chemotherapy·E B ChaïbiR Labia
Oct 6, 1999·Current Opinion in Microbiology·V J LeeM Yagisawa
Feb 13, 2001·Antimicrobial Agents and Chemotherapy·J M ClementsM G Hunter
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group
Feb 15, 2001·Expert Opinion on Investigational Drugs·O K KimJ F Barrett
Feb 15, 2001·Expert Opinion on Investigational Drugs·J KumarA M Krensky
Feb 15, 2001·Expert Opinion on Investigational Drugs·H M Yassin, L L Dever
May 17, 2001·Antimicrobial Agents and Chemotherapy·J A SilvermanT Li
May 31, 2001·Microbiology and Molecular Biology Reviews : MMBR·I Chopra, M Roberts
Sep 8, 2001·Drug Discovery Today·Z YuanR J. White
Sep 28, 2001·International Journal of Antimicrobial Agents·J Garau
Jan 5, 2002·Current Opinion in Pharmacology·I Chopra
Jul 5, 2005·Expert Opinion on Investigational Drugs·F P TallyF B Oleson

❮ Previous
Next ❯

Citations

May 17, 2003·Pulmonary Pharmacology & Therapeutics·Mario CazzolaMaria Gabriella Matera
Mar 9, 2005·Respiration; International Review of Thoracic Diseases·Mario Cazzola, Cesare Saltini
Jan 31, 2003·Expert Opinion on Investigational Drugs·Neil Woodford
Oct 1, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Bakheet Elsadek, Felix Kratz
Jun 10, 2011·European Journal of Medicinal Chemistry·Vyacheslav E SemenovVladimir S Reznik
Oct 3, 2007·Internal Medicine Journal·Z Harrington, D J Barnes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.